



Table II. Biological Activity of Benzimidazolyltriazoles

Compd no. <sup>a</sup>	Approx LD <sub>50</sub> , mg/kg ip	Anticonvulsant activity <sup>b</sup>		Potentiation <sup>b</sup> of pentobarbital sleeping time, min ± std dev
		Protection, %	24-hr mortality, %	
1	>1000	30	40	11.66 ± 6
2	>1000	70	10	23.16 ± 6
3	>1000	60	20	57.56 ± 14
4	>1000	70	10	45.83 ± 20
5	>1000	60	20	26.83 ± 7
6	>1000	50	40	24.50 ± 15
7	1000	40	50	53.66 ± 4
8	>1000	40	40	35.00 ± 17
9	>1000	40	40	44.33 ± 12
10	750	80	20	35.83 ± 19
11	1000	60	40	52.00 ± 13
12	1000	50	30	43.66 ± 19
13	1000	30	50	87.10 ± 15
14	1000	50	50	55.16 ± 22
15	>1000	40	60	43.66 ± 9
16	1000	70	40	60.50 ± 10
17	>1000	50	40	57.33 ± 10
18	>1000	60	40	59.00 ± 17

<sup>a</sup>Compounds are numbered as in Table I. <sup>b</sup>Compounds were administered at a dose of 100 mg/kg ip.

methylthio-1,2,4(*H*)-triazoles (IV). To a soln of the ester (III) (0.01 mole) in EtOH was added N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.015 mole), and the mixt was refluxed for 3–4 hr. Excess of EtOH was removed, and the solid thus obtained was collected by filtration, dried, and recrystd (EtOH); yield 60–70%.



**Acknowledgment.** The authors wish to express their thanks to Professor K. P. Bhargava and Dr. D. Dayal for their advice and encouragement. Grateful acknowledgment is made to Dr. M. L. Dhar and Dr. Nitya Anand of the Central Drug Research Institute, Lucknow, for providing microanalysis facilities and to the State Medical Research Council (U.P.), Lucknow, and the Indian Council of Medical Research, New Delhi, for providing financial assistance.

## References

- (1) G. Pellizzari and C. Massa, *Atti Reale. Accad. Naz. Lincei, Rend., Cl. Sci. Fis., Met. Natur.*, 10, 363 (1901); *J. Chem. Soc.*, 80 (1), 488 (1901).
- (2) C. Ainsworth, N. R. Easton, M. Livezey, D. E. Morrison, and W. R. Gibson, *J. Med. Chem.*, 5, 383 (1962).
- (3) Shinogi & Co. Ltd., French Patent M.6342(Cl-A61K,C 07d) (Nov 1968); Japan, *cf. Chem. Abstr.*, 74, 91166 (1971).
- (4) Hasegawa, Hajime, Mauruyama, and Hiroshi, Japanese Patent 70,39,541 (Cl.CO7d A61K) (Dec 12, 1970).
- (5) N. P. Buu. Hoi, P. Jacquignon, and J. P. Hoehinger, *Arzneim.-Forsch.*, 13, 865 (1963).
- (6) K. Chou and T. H. Tu, *Yao Hsueh Hsueh Pao*, 12 (6), 362 (1965).
- (7) V. K. Rastogi, R. C. Arora, J. N. Sinha, and S. S. Parmar, *J. Prakt. Chem.*, 312, 744 (1970).
- (8) R. P. Kohli, T. K. Gupta, S. S. Parmar, and R. C. Arora, *Jap. J. Pharmacol.*, 17, 409 (1967).
- (9) C. A. Winter, *J. Pharm. Exp. Ther.*, 94, 1 (1948).

- (10) J. S. Shukla, H. H. Singh, and S. S. Parmar, *J. Prakt. Chem.*, 311, 523 (1969).
- (11) M. H. Shah, M. Y. Mhasalkar, N. N. Varaya, R. A. Bellare, and C. V. Deliwala, *Indian J. Chem.*, 5, 391 (1967).

## Substituted Indolebenzylhydrazines as Anticonvulsants

V. K. Agarwal, T. K. Gupta, and Surendra S. Parmar\*

*Department of Pharmacology and Therapeutics, King George's Medical College, Lucknow-3, India.*

*Received January 13, 1972*

The presence of a trimethoxy moiety has been shown to be responsible for pharmacological properties of reserpine<sup>1-8</sup> and other compounds associated with CNS activity. The MAO-inhibitory property exhibited by indolehydrazines<sup>9</sup> possessing CNS activity led to the synthesis of dimethoxy- and trimethoxyindolebenzylhydrazines with a view to evaluating their ability to afford protection against pentylenetetrazole-induced seizures.

**Anticonvulsant activity** was detd by injecting substituted indolebenzylhydrazines ip in a 5% aqueous suspension of gum acacia at a dose of 100 mg/kg in groups of 10 mice of either sex weighing 20–25 g. Four hours after the administration of the test compounds pentylenetetrazole was injected sc under the loose skin of the back in a dose of 80 mg/kg. This dose of pentylenetetrazole has been shown to cause convulsions within 1 hr of administration and to produce 100% mortality within 24 hr. The mice were observed for the next 60 min for occurrence of seizures. Animals devoid of even a threshold convulsion were considered protected.

## Results and Discussion


As is evident from Table I anticonvulsant activity ranging from 10 to 50% was exhibited by the test compounds. Maximum protection against pentylenetetrazole-induced seizures, observed with 4, was found to correspond with lowest mortality. The anticonvulsant properties of these compounds parallel their ability to protect against death in pentylenetetrazole-treated mice during a 24-hr period. Those indolebenzylhydrazines containing a trimethoxyphenyl group were found to exhibit greater anticonvulsant activity than those possessing a dimethoxyphenyl group. These results indicated that substitution at position 5 of an indole nucleus possessing a trimethoxyphenyl moiety influenced their anticonvulsant activity, in the order of CH<sub>3</sub> > OCH<sub>3</sub> > H. It is hoped that further detailed pharmacological studies with these and related indolebenzylhydrazines could ultimately lead to the development of therapeutic agents for diseases of the CNS.

## Experimental Section

**Substituted Phenylhydrazines.** *p*-Methylphenylhydrazine and *p*-methoxyphenylhydrazine were synthesized according to the methods reported earlier.<sup>10</sup>


**Ethyl Substituted Indole-3-acetates.** Ethyl substituted indole-3-acetates were synthesized by cyclization of substituted phenylhydrazines and ethyl levulinate in 2*N* EtOH-HCl. The crude products were isolated with ether and washed with Na<sub>2</sub>CO<sub>3</sub> soln and finally with H<sub>2</sub>O. On distilling the solvent the esters were isolated.<sup>9</sup>

**Substituted Indole-3-acetylhydrazines.** Ethyl substituted indole-3-acetates (0.1 mole) were refluxed with N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.15 mole, 80%) in 25 ml of absolute EtOH for 8 hr. On distilling the excess of solvent

Table I. N<sup>1</sup>-Substituted Indole-3-acetyl-N<sup>2</sup>-(3',4'-dimethoxy/3',4',5'-trimethoxybenzyl)hydrazines and Their Anticonvulsant Activity


No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	Mp, <sup>a</sup> °C	Yield, %	Solvent of crystn <sup>b</sup>	Formula <sup>c</sup>	Anticonvulsant activity	
									Protection, %	Mortality, 24 hr, %
1	CH <sub>3</sub>	CH <sub>3</sub> O	CH <sub>3</sub> O	H	225	60	EtOH	C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>3</sub>	30	30
2	H	CH <sub>3</sub> O	CH <sub>3</sub> O	H	220	70	EtOH	C <sub>20</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>	10	40
3	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	H	215	75	PE	C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub>	20	50
4	CH <sub>3</sub>	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	280	60	D	C <sub>22</sub> H <sub>27</sub> N <sub>3</sub> O <sub>4</sub>	50	20
5	H	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	120	40	D	C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub>	30	50
6	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	112	50	Et <sub>2</sub> O	C <sub>22</sub> H <sub>27</sub> N <sub>3</sub> O <sub>5</sub>	10	70

<sup>a</sup>Melting points were taken in open capillary tubes. <sup>b</sup>PE = Petr ether; D = dioxane. <sup>c</sup>All compds were analyzed for C, H, and N and analyses were found within acceptable limits.

Table II. N<sup>1</sup>-Substituted Indole-3-acetyl-N<sup>2</sup>-(3',4'-dimethoxy/3',4',5'-trimethoxybenzylidene)hydrazines


No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	Mp, °C <sup>a</sup>	Yield, %	Solvent <sup>b</sup>	Formula <sup>c</sup>
1	CH <sub>3</sub>	CH <sub>3</sub> O	CH <sub>3</sub> O	H	198	65	EtOH	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>
2	H	CH <sub>3</sub> O	CH <sub>3</sub> O	H	192	60	PE	C <sub>20</sub> H <sub>21</sub> N <sub>3</sub> O <sub>3</sub>
3	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	H	191	70	PE	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>4</sub>
4	CH <sub>3</sub>	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	210	65	EtOH	C <sub>22</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub>
5	H	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	180	70	EtOH	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>4</sub>
6	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	CH <sub>3</sub> O	190	60	EtOH	C <sub>22</sub> H <sub>25</sub> N <sub>3</sub> O <sub>5</sub>

<sup>a</sup>Melting points were taken in open capillary tubes. <sup>b</sup>PE = petr ether. <sup>c</sup>All compds were analyzed for C, H, and N and analyses were found within acceptable limits.

the hydrazides which separated out were filtered and recrystd with appropriate solvents.

**Substituted Indolebenzylidenehydrazines.** A mixt of 0.01 mole of substituted indole-3-acetylhydrazine and substituted (dimethoxy- or trimethoxy)benzaldehyde (0.01 mole) in EtOH (50 ml) was refluxed for 2 hr. The reaction mixt was filtered hot and concd *in vacuo*. The solid compounds which sepd out on cooling were crystd from the appropriate solvents (Table II).

**Substituted Indolebenzylhydrazines.** A soln of 0.05 mole of substituted indolebenzylidenehydrazines in 100 ml of dioxane or THF was hydrogenated with 0.1 g of PtO<sub>2</sub> catalyst in a Parr hydrogenation apparatus at an initial pressure of 2.8 kg/cm<sup>2</sup>. The required amount of hydrogen was absorbed in 15 hr. Filtration and removal of the solvent under reduced pressure left a residue which was crystd by dissolving in a minimum amount of EtOH and adding petroleum ether (bp 40–60°).

**Acknowledgments.** The authors wish to express their thanks to Professor K. P. Bhargava and Dr. J. P. Barthwal for their advice and encouragement and to Dr. M. L. Dhar and Dr. Nitya Anand of the Central Drug Research Institute, Lucknow, for providing microanalysis facilities. Grateful acknowledgment is made to the State Council of Scientific

and Industrial Research, Lucknow for providing financial assistance to one of us (V. K. A.).

## References

- (1) R. Benington, R. D. Morin, L. C. Clark, and R. P. Fox, *J. Org. Chem.*, **23**, 2034 (1958).
- (2) M. A. Karim, W. H. Linnell, and L. K. Sharp, *J. Pharm. Pharmacol.*, **12**, 74 (1960).
- (3) M. A. Karim, W. H. Linnell, and L. K. Sharp, *ibid.*, **12**, 82 (1960).
- (4) P. C. Dandiya and M. K. Menon, *Brit. J. Pharmacol.*, **20**, 436 (1963).
- (5) P. C. Dandiya and J. D. Sharma, *Indian J. Med. Res.*, **50**, 46 (1962).
- (6) L. H. Schlager, *Arzneim.-Forsch.*, **13**, 226 (1963).
- (7) (a) J. Borsay, *ibid.*, **8**, 3 (1960); *Chem. Abstr.*, **56**, 5371 (1962); (b) J. R. Boissier, P. Simon, and P. Fichelle, *J. Therapie*, **20**, 401 (1965); *Chem. Abstr.*, **63**, 22856 (1965).
- (8) G. Cronheim, J. T. Gourzis, and I. M. Toekes, *Science*, **128**, 1570 (1958).
- (9) K. Shanker, V. K. Agarwal, R. J. Shelvraj, and S. S. Parmar, *J. Med. Chem.*, **12**, 324 (1969).
- (10) K. G. Blackie and W. H. Perkin, *J. Chem. Soc.*, 296 (1964).

## Book Reviews

**Search for New Drugs.** Edited by Alan A. Rubin, with 12 contributors. Marcel Dekker, New York, N. Y. 1972. x + 452 pp. 16 × 24 cm. \$19.50.

Fortuitous discovery of clinically useful drugs, so prevalent earlier in the century, is becoming less probable every day. The smaller number of clinical trials, dictated by more severe governmental restrictions, is the final pinnacle protruding from an ocean of obstacles in drug research. These obstacles begin with the uncertainties of even the most sophisticated methods of drug design in the chemical

laboratory. The most formidable difficulty is the predictability of the success of a drug in human medicine even if animal model experiments hold out promise. The book under discussion examines these pharmacological hurdles in several fields. In three of them drugs are known to suppress symptoms of the diseases, but with varying success only. They are antiinflammatory, antiulcer, and psychotropic drugs. The three chapters probe the possibility of discovering tests for curative agents.

Four other chapters deal with drugs—β-adrenergic blocking agents,